Compare Enact Holdings Inc (ACT) vs Alnylam Pharmaceuticals, Inc. (ALNY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Enact Holdings Inc vs Alnylam Pharmaceuticals, Inc. — how do they compare? Enact Holdings Inc trades at $45.27 (market cap $6.35B), while Alnylam Pharmaceuticals, Inc. trades at $321.52 (market cap $42.94B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 6.8× Enact Holdings Inc's market cap, and Enact Holdings Inc pays a 1.91% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ACT | ALNY | |
|---|---|---|
Market Cap | $6.35B | $42.94B |
Sector | Technology | Health |
52-Week High | $45.71 | $491.22 |
52-Week Low | $34.39 | $278.09 |
Enterprise Value | $6.55B | $41.20B |
Dividend Yield | 1.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACT trades at $45.69, up 0.77% today, with a bullish technical signal and strong moving averages. The stock shows robust fundamentals with a net income margin of 54.49% and a P/E ratio of 9.89. Recent news includes a 14% dividend increase announced on May 5, 2026, and Q1 2026 earnings that met expectations. Analyst consensus is a $47.50 price target with a mix of buy and hold ratings.
Outlook remains positive due to high profitability and dividend growth, but risks include earnings volatility and market sensitivity. Upside is supported by institutional sentiment and consistent cash flow, though investors should monitor execution against future earnings estimates.
Alnylam Pharmaceuticals (ALNY) trades at $321.59, up 2.82% today, with a bullish technical signal supported by moving averages. The company reported strong revenue growth, reaching $3.71 billion in 2025, and turned profitable with net income of $313.75 million. Recent news highlights its AI partnerships and expanding drug pipeline as key growth drivers.
The outlook is positive, with a consensus price target of $435.40 implying 35% upside, driven by robust revenue growth and pipeline advancements. Risks include dependence on key drug Amvuttra and high valuation multiples. Analyst sentiment is strongly bullish, with 75% recommending Buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enact Holdings Inc
Enact Holdings is a leading private mortgage insurance provider in the U.S. It partners with lenders to offer credit enhancement and risk management solutions, helping more borrowers achieve and maintain homeownership.
Read more on ACT →About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →
